- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05921058
The Effects of Mesenchymal Stem Cell Secretome in Lupus Patients
June 25, 2023 updated by: Arief Nurudhin, Universitas Sebelas Maret
This research is a clinical trial of administering mesenchymal stem cell secretome to lupus patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This research is experimental.
The study was conducted on 30 SLE patient subjects.
the treatment group who got the mesenchymal stem cell secretome on the 1st, 2nd day, 3rd, 4th, 5th, 6th, 7th, 14th, 21st, and 28th days.
ESR, hs-CRP, C3, C4, interlukin 6, anti-ds-DNA antibody, MEX SLEDAI score, and assessment of drug side effects before and after therapy were collected.
Statistical test with paired difference test with p < 0.05
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Middle Java
-
Surakarta, Middle Java, Indonesia
- Moewardi General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Lupus paatients
Exclusion Criteria:
- Pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Messenchymal stem cell secretome
The hypoxic mesenchymal stem cell secretome has been developed up to chapter 7, stored at -196 C to -135 C in cryopreservation, and has passed quality tests.
|
Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
Other Names:
|
Placebo Comparator: Placebo
Nacl 0,9% infusion
|
NaCl 0,9% infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lupus Disease activity
Time Frame: Change of Lupus Disease Activity at 1 months
|
The data collected were MEX SLEDAI score (range 0-32) before and after therapy.
|
Change of Lupus Disease Activity at 1 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nurhasan Agung Prabowo, MD, Universitas Sebelas Maret
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Pratama YS, Pradiptakirana R, Rachmah A, Prabowo NA. Autoimmune Thrombocytopenia in SLE and COVID-19. Eur J Case Rep Intern Med. 2021 Nov 3;8(11):002863. doi: 10.12890/2021_002863. eCollection 2021.
- Sholihah MM, Kusuma TRH, Hanif MI, Prabowo NA. Letter to the Editor on Type 1 diabetes onset triggered by COVID-19. Acta Diabetol. 2021 Sep;58(9):1283-1284. doi: 10.1007/s00592-021-01761-3. Epub 2021 Jun 28. No abstract available.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2022
Primary Completion (Actual)
December 30, 2022
Study Completion (Actual)
March 9, 2023
Study Registration Dates
First Submitted
March 9, 2023
First Submitted That Met QC Criteria
June 25, 2023
First Posted (Actual)
June 27, 2023
Study Record Updates
Last Update Posted (Actual)
June 27, 2023
Last Update Submitted That Met QC Criteria
June 25, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- NAP05
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lupus Erythematosus
-
BiogenRecruitingSubacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus ErythematosusUnited States, Italy, Korea, Republic of, Taiwan, Argentina, Chile, Spain, Canada, Serbia, France, Germany, Japan, Brazil, United Kingdom, Puerto Rico, Bulgaria, Portugal, Switzerland, Philippines, Saudi Arabia, Sweden, Mexico, Poland, Hunga... and more
-
BiogenEnrolling by invitationSubacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus ErythematosusFrance, Spain, United States, Sweden
-
Florida Academic Dermatology CentersUnknownDiscoid Lupus Erythematosus (DLE)United States
-
Bristol-Myers SquibbActive, not recruitingLupus Erythematosus, Discoid | Lupus Erythematosus, Subacute CutaneousMexico, Argentina, Australia, United States, France, Germany, Poland, Taiwan
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
AmgenCompleted
-
LEO PharmaTerminatedDiscoid Lupus ErythematosusUnited States, France, Germany, Denmark
-
University of RochesterIncyte CorporationCompletedDiscoid Lupus ErythematosusUnited States
-
Massachusetts General HospitalNovartisWithdrawnDiscoid Lupus ErythematosusUnited States
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
Clinical Trials on Secretome
-
PT. Prodia Stem Cell IndonesiaRecruitingOsteoarthritis, KneeIndonesia
-
Yohanes Firmansyah, dr, MH, MMTarumanagara UniversityCompletedCM-MSC ; Stem Cell ; Trophic Ulcer ; Leprosy ; Morbun Hansen; SecretomIndonesia
-
I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioRecruiting
-
Acorn Biolabs Inc.Enrolling by invitation
-
COR clinic of Regenerative MedicineCompleted
-
Dr. Soetomo General HospitalDr. Ramelan Naval Hospital; Airlangga University Hospital; Sidoarjo General Hospital and other collaboratorsRecruiting
-
PT. Prodia Stem Cell IndonesiaRecruitingNasopharyngeal CancerIndonesia
-
Stem Cell and Cancer Research IndonesiaProvincial Government of Central Java, IndonesiaRecruitingTreatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in IndonesiaCovid-19 | Cytokine StormIndonesia
-
Dr. dr. Lili Legiawati, SpKK(K)PT. Kimia Farma (Persero) Tbk; Ministry of Education, Culture, Research, and...Active, not recruiting
-
Avicenna Research InstituteTehran University of Medical SciencesCompleted